Revolutionizing Skin Health with our Advanced Engineered Biotherapeutics

Projektinformationen

SkinEngineering

ID Finanzhilfevereinbarung: 101203545

DOI

10.3030/101203545

EK-Unterschriftsdatum 21 März 2025

Startdatum 1 Mai 2025

Enddatum 30 April 2028

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

Keine Daten

EU-Beitrag

€ 2 499 999,00

Koordiniert durch

UNIVERSIDAD POMPEU FABRA
Spain

Periodic Reporting for period 1 - SkinEngineering (Revolutionizing Skin Health with our Advanced Engineered Biotherapeutics)

Berichtszeitraum: 2025-05-01 bis 2026-04-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

SkinEngineering addresses the growing need for innovative and sustainable therapies for chronic inflammatory skin diseases, such as acne, where current treatments are often associated with limited efficacy, recurrence, adverse effects and increasing antimicrobial resistance. The project develops a next-generation engineered live biotherapeutic platform designed to deliver therapeutic molecules directly at the skin surface through the natural skin microbiome, offering a targeted and potentially safer alternative to conventional therapies.

The project contributes to the European priorities of strengthening biotechnology innovation, advancing precision medicine, reducing antibiotic use and accelerating the translation of research into clinical and commercial applications. By integrating synthetic biology, microbiome engineering, preclinical validation, manufacturing development and regulatory planning, SkinEngineering aims to advance its technology towards clinical translation and future commercialization.

The expected pathway to impact includes the generation of a novel therapeutic platform with broad applicability to inflammatory skin diseases, the creation of a European biotechnology company, the strengthening of the European microbiome innovation ecosystem, and the long-term improvement of patient care through more effective and sustainable therapeutic solutions.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the first reporting period, the project advanced the development of an engineered live biotherapeutic platform for inflammatory skin diseases. Activities focused on optimizing the bacterial platform, establishing preclinical efficacy and safety studies, developing biocontainment strategies, initiating manufacturing and regulatory activities, and strengthening the translational pathway towards future clinical development. The project achieved its main milestones and established a solid foundation for the next phase of development.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The project generated significant progress towards the development of an engineered live biotherapeutic platform for inflammatory skin diseases, strengthening its scientific, technological and translational maturity. The results support further preclinical validation and future clinical development while contributing to innovation in microbiome-based therapeutics.

To maximize impact, the project will require continued preclinical validation, demonstration in relevant models, regulatory support for genetically engineered live biotherapeutic products, GMP manufacturing scale-up, intellectual property protection, access to public and private funding, industrial partnerships, and international commercialization activities. These actions will facilitate successful market uptake and future clinical translation.